TEE
MRKR icon

Tibra Equities Europe’s Marker Therapeutics MRKR Stock Holding History

Tibra Equities Europe’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-6,018
Closed -$397K – 380
2019
Q1 		$397K Buy
+6,018
New +$351K 0.04% 289

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Tibra Equities Europe's MRKR Position: Q2 2019 in Review

Tibra Equities Europe sold out of Marker Therapeutics (MRKR) in Q2 2019, closing a stake of 6,018 shares — an estimated $397K sold.

Tibra Equities Europe first reported a position in MRKR in Q1 2019 and held it in 1 quarter. The position peaked at $397K in Q1 2019. 70 funds tracked by Wall St. Rank hold MRKR as of Q2 2019.

  • Tibra Equities Europe reported no remaining Marker Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 6,018 Marker Therapeutics shares in Q2 2019, an estimated $397K.
  • Tibra Equities Europe first reported a position in Marker Therapeutics in Q1 2019 and held it in 1 quarter.
  • Tibra Equities Europe's Marker Therapeutics position peaked at $397K in Q1 2019.
  • 70 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.